SNC 80
(Synonyms: (+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺,NIH 10815) 目录号 : GC11355A selective δ-opioid receptor agonist
Cas No.:156727-74-1
Sample solution is provided at 25 µL, 10mM.
SNC 80 is a selective nonpeptide agonist of the δ-opioid receptor (Ki = 0.18 nM, IC50 = 2.73 nM) that is over 2,000-fold less effective at the μ-opioid receptor.[1],[2],[3] It effectively activates µ/δ receptor heteromers (EC50 = 52.8 nM) but not κ/δ or μ/κ heteromers.[4] SNC 80 has antinociceptive as well as pro-convulsant effects in vivo.[1],[2],[5]
Reference:
[1]. Bilsky, E.J., Calderon, S.N., Wang, T., et al. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. Journal of Pharmacology and Experimental Therapeutics 273(1), 359-366 (1995).
[2]. Calderon, S.N., Rothman, R.B., Porreca, F., et al. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A highly selective, nonpeptide δ opioid receptor agonist. Journal of Medicinal Chemistry 37(14), 2125-2128 (1994).
[3]. Knapp, R.J., Santoro, G., De Leon, I.A., et al. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. Journal of Pharmacology and Experimental Therapeutics 277(3), 1284-1291 (1996).
[4]. Metcalf, M.D., Yekkirala, A.S., Powers, M.D., et al. The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors. ACS Chem.Neurosci. 3(7), 505-509 (2012).
[5]. Danielsson, I., Gasior, M., Stevenson, G.W., et al. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacology, Biochemistry, and Behavior 85(2), 428-434 (2006).
Cas No. | 156727-74-1 | SDF | |
别名 | (+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺,NIH 10815 | ||
化学名 | 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-N,N-diethylbenzamide | ||
Canonical SMILES | O=C(C1=CC=C(C=C1)[C@H](C2=CC=CC(OC)=C2)N3[C@@H](C)CN(CC=C)[C@H](C)C3)N(CC)CC | ||
分子式 | C28H39N3O2 | 分子量 | 449.64 |
溶解度 | 0.2 mg/ml in DMSO, 0.2 mg/ml in DMF | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.224 mL | 11.12 mL | 22.24 mL |
5 mM | 0.4448 mL | 2.224 mL | 4.448 mL |
10 mM | 0.2224 mL | 1.112 mL | 2.224 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet